The use of glucagon-like peptide-1 (GLP-1) receptor agonists for managing type 2 diabetes mellitus and obesity has increased significantly in recent years. These medications reduce blood glucose levels by promoting glucose-dependent insulin secretion, inhibiting glucagon release, slowing gastric emptying, and decreasing food cravings.
Elsie Burger (Sun,) studied this question.